Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors.
Melanoma
human leukocyte antigen (HLA)
immunogenicity
major histocompatibility complex (MHC)
neoantigens
Journal
Cancer informatics
ISSN: 1176-9351
Titre abrégé: Cancer Inform
Pays: United States
ID NLM: 101258149
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
03
2024
accepted:
24
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Host immunogenetics (Human Leukocyte Antigen, HLA) play a critical role in the human immune response to melanoma, influencing both melanoma prevalence and immunotherapy outcomes. Beneficial outcomes hinge on the successful binding of epitopes of melanoma antigens to HLA Class I molecules for an effective engagement of cytotoxic CD8+ lymphocytes and subsequent elimination of the cancerous cell. This study evaluated the binding affinity and immunogenicity of HLA Class I to melanoma tumor antigens to identify alleles best suited to facilitate elimination of melanoma antigens. In this study, we used freely available software tools to determine We identified the following 9 HLA Class I alleles with very high immunogenicity and binding affinity against all 11 melanoma antigens: A*02:14, B*07:10, B*35:10, B*40:10, B*40:12, B*44:10, C*07:11, and C*07:13, and C*07:14. These 9 HLA alleles possess the potential to aid in the elimination of melanoma both by themselves and by enhancing the beneficial effect of immune checkpoint inhibitors.
Identifiants
pubmed: 39206277
doi: 10.1177/11769351241274160
pii: 10.1177_11769351241274160
pmc: PMC11350539
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11769351241274160Informations de copyright
© The Author(s) 2024.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.